Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;25(139):65-70.
doi: 10.1183/16000617.0053-2015.

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer

Markus Glatzer  1 , Olgun Elicin  2 , Sara Ramella  3 , Ursula Nestle  4 , Paul Martin Putora  5
Affiliations
Review

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer

Markus Glatzer et al. Eur Respir Rev. 2016 Mar.

Abstract

Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsmall cell lung cancer (NSCLC). Treatment outcomes have improved over the last decades. Several treatment regimens have been shown effective and safe. This review summarises the results of significant studies between 1996 and 2015 on concomitant and sequential radiochemotherapy regimens and radiation dose per fraction. Beside therapy regimens, optimised radiotherapy planning is indispensable to improve outcome and minimise radiation-induced toxicity. An insight into the rationale of radiotherapy planning for stage III NSCLC is also provided.

PubMed Disclaimer

Conflict of interest statement

Provenance: Submitted article, peer reviewed.

References

    1. Bradley JD, Paulus R, Komaki R, et al. . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187–199. - PMC - PubMed
    1. Putora PM, Früh M, Kern L. The place of radiotherapy in the palliative management of NSCLC. Breathe 2011; 8: 134–143.
    1. Riquet M, Mordant P, Fabre-Guillevin E, et al. . Long-term survival with surgery as part of a multimodality approach for N3 lung cancer. Eur J Cardiothorac Surg 2013; 44: 1117–1122. - PubMed
    1. Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. . Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines. Chest 2007; 132: Suppl 3, 243S–265S. - PubMed
    1. Cox JD, Azarnia N, Byhardt RW, et al. . A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8: 1543–1555. - PubMed

MeSH terms